[Press Release] US Pressure on India Threatens Access to Medicines
South Africa 2011 © Jose Cendon
A patient at Lizo Nobanda TB Care Center in Khayelitsha township takes her pills.
NEW DELHI/NEW YORK, SEPTEMBER 25, 2013—On the eve of a meeting between US president Barack Obama and Indian prime minister Manmohan Singh at the White House, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today warned that India faces retaliatory political pressure from the US government and pharmaceutical industry for its efforts to legally limit abusive patenting practices and to increase access to affordable generic m...
Source: MSF News - December 3, 2013 Category: Global & Universal Source Type: news
ARIAD terminates Phase III study of ponatinib in newly diagnosed CML patients
ARIAD Pharmaceuticals is terminating the Phase III EPIC ('Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia') trial of its oral drug candidate Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukaemia (CML). (Source: Drug Development Technology)
Source: Drug Development Technology - October 21, 2013 Category: Pharmaceuticals Source Type: news
New treatment regimen may prevent fatal leukemia progression
Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs, according to a study in The Journal of Experimental Medicine. Chronic myeloid leukemia (CML) is an aggressive cancer of the blood that is often treated with a drug called Imatinib (a.k.a. Gleevec). Although Gleevec is highly effective, some cancer cells can develop resistance to the drug. The mechanism that drives this resistance is not completely understood, but there is evidence that cancerous stem-like cells are particularly resistant and help to perpetuate disease... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 9, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
US Pressure on India Threatens Access to Medicines
South Africa 2011 © Jose Cendon
A patient at Lizo Nobanda TB Care Center in Khayelitsha township takes her pills.
NEW DELHI/NEW YORK, SEPTEMBER 25, 2013—On the eve of a meeting between US president Barack Obama and Indian prime minister Manmohan Singh at the White House, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today warned that India faces retaliatory political pressure from the US government and pharmaceutical industry for its efforts to legally limit abusive patenting practices and to increase access to affordable generic m...
Source: MSF News - September 25, 2013 Category: Global & Universal Source Type: news
Trial Suggests Imatinib Discontinuation Safe, Some Responses Persist
Evidence continues to mount that discontinuing imatinib treatment for chronic myeloid leukemia (CML) in the chronic phase is safe. A new phase II Dutch and Belgian study showed only about two-thirds of patients relapsed after discontinuing treatment with imatinib and cytarabine, and all patients remained sensitive to imatinib after relapse. (Source: Cancer Network)
Source: Cancer Network - September 16, 2013 Category: Cancer & Oncology Source Type: news
ARIAD reaches 50 percent patient enrollment in Phase 3 EPIC trial of Iclusig
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) has announced enrollment of fifty percent of the patients planned in its randomized Phase 3 trial of Iclusig® (ponatinib) in adult patients with newly diagnosed chronic myeloid leukemia (CML). The trial, formally known as EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia), is designed to provide definitive clinical data to support regulatory approval of ponatinib in treatment-naïve CML patients... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 6, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
First-Line Treatment for Patients With CML in Chronic Phase: Why Imatinib Is an Appropriate Choice
I am very comfortable in using imatinib as initial therapy in most patients who present in chronic phase, with the possible exception of patients with more advanced disease and higher Sokal scores. (Source: Cancer Network)
Source: Cancer Network - August 15, 2013 Category: Cancer & Oncology Source Type: news
Imatinib Is Yet Another Option in Advanced MelanomaImatinib Is Yet Another Option in Advanced Melanoma
The drug has been recommended by the National Comprehensive Cancer Network as new trials show efficacy. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Preventing Death Of Eggs During Chemotherapy
Young women who have cancer treatment often lose their fertility because chemotherapy and radiation can damage or kill their immature ovarian eggs, called oocytes. Now, Northwestern Medicine® scientists have found the molecular pathway that can prevent the death of immature ovarian eggs due to chemotherapy, potentially preserving fertility and endocrine function. Scientists achieved this in female mice by adding a currently approved chemotherapy drug, imatinib mesylate, to another chemotherapy drug cisplatin... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 20, 2013 Category: Consumer Health News Tags: Fertility Source Type: news
Preventing eggs' death from chemotherapy
(Northwestern University) Young women who have cancer treatment often lose their fertility because chemotherapy and radiation can damage or kill their immature ovarian eggs, called oocytes. Now, Northwestern Medicine® scientists have found the molecular pathway that can prevent the death of immature ovarian eggs due to chemotherapy, potentially preserving fertility and endocrine function. Scientists achieved this in mice by adding a currently approved chemotherapy drug, imatinib mesylate, to another chemotherapy drug cisplatin. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - June 17, 2013 Category: Global & Universal Source Type: news
Intermittent Imatinib for Elderly CML Patients Shows Promise
A phase II study found that an alternative imatinib treatment schedule for elderly patients with chronic myeloid leukemia (CML) could be an effective way to reduce dosing requirements of the drug. (Source: Cancer Network)
Source: Cancer Network - June 15, 2013 Category: Cancer & Oncology Source Type: news
Imatinib Discontinuation in Chronic Phase CML Doesn’t Always Lead to Relapse
Almost half of patients with chronic-phase chronic myeloid leukemia (CML) who discontinued imatinib treatment did not relapse, according to results of a prospective study. Those who did relapse showed continued sensitivity to imatinib when treatment started again. (Source: Cancer Network)
Source: Cancer Network - June 14, 2013 Category: Cancer & Oncology Source Type: news
Imatinib Failure-Free Survival In Patients With Gastrointestinal Stromal Tumors
Interim results of an EORTC intergroup trial have confirmed that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/ intermediate-risk GIST. In the high-risk subgroup, a non-statistically significant trend in favor of the adjuvant arm was observed in terms of Imatinib failure-free survival... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 30, 2013 Category: Consumer Health News Tags: GastroIntestinal / Gastroenterology Source Type: news
EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
(European Organisation for Research and Treatment of Cancer) These are the interim results of an EORTC intergroup trial have confirmed that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/ intermediate-risk GIST. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2013 Category: Global & Universal Source Type: news
Nilotinib Associated With Increased Peripheral Artery Disease Rate in CML
Two studies found higher rates of peripheral artery occlusive disease in nilotinib-treated chronic myeloid leukemia patients than in imatinib-treated patients. (Source: Cancer Network)
Source: Cancer Network - May 13, 2013 Category: Cancer & Oncology Source Type: news
